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The link between changes in a subjectʼs metabolic syndrome components and her estimated glomerular 
ﬁltration rate (eGFR) was evaluated in healthy Japanese women.  We used data for 53 Japanese women 
(46.0±10.9 years) with a 1-year follow up.  eGFR was deﬁned by a new equation developed for Japan.  
There were no signiﬁcant relationships between eGFR and clinical parameters at baseline.  Subjects 
were given advice for dietary and lifestyle improvement.  At the 1-year follow up,  eGFR was signiﬁ-
cantly increased.  In addition,  changes in eGFR were weakly correlated with systolic blood pressure 
(r＝－0.306,  p＝0.0260).  A decrease in systolic blood pressure may be associated with improving eGFR 
in Japanese women.
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hronic kidney disease (CKD) is a common disor-
der and has become a public health challenge 
[1].  For example,  about 20ｵ of adults have CKD,  
which is deﬁned as kidney damage or a glomerular 
ﬁltration rate (GFR) ＜60ml/min/1.73m2 for at least 
3 months regardless of cause,  and 4. 1ｵ have moder-
ate or severe CKD [2].  We have also previously 
reported in a cross-sectional study that the estimated 
glomerular ﬁltration rate (eGFR) [3] in men with 
abdominal obesity and in women with hypertension was 
signiﬁcantly lower than that in subjects without these 
components of metabolic syndrome [4].  However,  
whether decreases in metabolic syndrome components 
are beneﬁcial for improving eGFR,  and what eﬀects 
this has on eGFR remain to be investigated in a longi-
tudinal study.  
　 In this study,  we evaluate the link between changes 
in eGFR and changes in metabolic syndrome compo-
nents in Japanese women with a 1-year follow up.
Subjects and Methods
　 Subjects. We used data for 53 Japanese 
women,  aged 46.0±10.9 years,  who met the following 
criteria: (1) received a health check-up including 
special health guidance and a follow-up check-up 
1-year later,  (2) received anthropometric measure-
ments,  fasting blood examination and blood pressure 
measurements as part of the annual health check-up,  
(3) received no medications for diabetes,  hyperten-
sion,  and/or dyslipidemia,  and (4) provided written 
informed consent (Table 1).  
C
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　 At the ﬁrst health check-up,  all subjects were 
given instructions by well-trained medical staﬀ on how 
to change their lifestyle as special health guidance.  
Nutritional instruction was provided with a well-
trained nutritionist,  who planned a diet for each sub-
ject based on their data and provided simple instruc-
tions (i. e.  not to eat too much and to consider balance 
when they eat).  Exercise instruction was also pro-
vided by a well-trained physical therapist,  who 
encouraged each subject to increase their daily amount 
of steps walked.
　 Ethical approval for the study was obtained from 
the Ethical Committee of Okayama Health 
Foundation.
　 Anthropometric and body composition mea-
surements. Anthropometric and body composi-
tions were evaluated based on the following 
parameters: height,  body weight and abdominal cir-
cumference.  Body mass index (BMI) was calculated by 
weight / [height]2,  in kg/m2.  Abdominal circumfer-
ence was measured at the umbilical level in standing 
subjects after normal expiration [5].  
　 Blood pressure measurements at rest.
Resting systolic and diastolic blood pressures were 
measured indirectly using a mercury sphygmomanom-
eter placed on the right arm of the seated participant 
after at least 15 min of rest.
　 Urine examination. Urine samples were col-
lected from the second- morning urine (before 10 
a. m. ) and subjected to examination within 1 h.  The 
urine examination was performed using urine test 
strips (BAYER,  Tokyo,  Japan).  The reagent strip 
was dipped directly into the urine sample.  Just after 
dipping,  the sample was graded as －: negative,  
±: trace positive,  ＋: positive (30mg/dl),  2＋: posi-
tive (100mg/dl),  3＋: positive (300mg/dl) or 4
＋: positive (1,000mg/dl) by comparison with a stan-
dard color chart found on the containerʼs label.
　 Blood sampling and assays. We measured 
overnight fasting serum levels of creatinine (Cr) 
(enzymatic method),  high-density lipoprotein (HDL) 
cholesterol,  triglycerides (L Type Wako Triglyc-
eride・H,  Wako Chemical,  Osaka,  Japan) and plasma 
glucose.  eGFR was calculated using the following 
equation: eGFR (ml/min/1.73m2)＝194×Cr－1.094×
Age－0.287×0.739 (a constant derived speciﬁcally for 
women) [3].  Reduced eGFR was deﬁned as an eGFR 
＜60ml/min/1.73m2.
　 Deﬁnition of metabolic syndrome. Women 
with an abdominal circumference in excess of 90cm 
were deﬁned as having metabolic syndrome if they also 
had 2 or more of the following components: 1) 
Dyslipidemia: triglycerides ≥ 150mg/dl and/or HDL 
cholesterol＜40mg/dl,  2) High blood pressure:  
blood pressure ≥ 130/85mmHg,  3) Impaired glucose 
tolerance: fasting plasma glucose ≥ 110mg/dl [5].  
　 Statistical analysis. Data are expressed as 
means ± standard deviation (SD).  A statistical analy-
sis was performed using a paired t test: p＜0.05 was 
considered to be statistically signiﬁcant.  Pearsonʼs 
correlation coeﬃcients were calculated and used to test 
the signiﬁcance of the linear relationship among con-
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Table 1　 Clinical characteristics and changes in parameters with 1-year follow up
Baseline Follow up p
Number of Subjects 53
Age 46.0 ±  10.9
Height (cm) 156.1 ±  4.3
Body weight (kg) 62.4 ±  8.8 60.9 ±  8.5 0.0002
Body mass index (kg/m2) 25.6 ±  3.3 25.0 ±  3.3 0.0002
Abdominal circumference (cm) 78.7 ±  8.1 76.6 ±  8.3 0.0005
Systolic blood pressre (mmHg) 121.5 ±  14.1 119.8 ±  15.4 0.2772
Diastolic blood pressure (mmHg) 76.2 ±  9.4 74.6 ±  10.8 0.2245
Triglyceride (mg/dl) 98.2 ±  65.8 95.8 ±  62.1 0.7065
HDL cholesterol (mg/dl) 64.5 ±  14.5 64.6 ±  14.9 0.9362
Blood sugar (mg/dl) 95.1 ±  9.4 93.8 ±  9.3 0.2018
Cr (mg/dl) 0.58 ±  0.09 0.56 ±  0.10 0.0148
eGFR (ml/min/1.73m2) 90.0 ±  17.9 94.2 ±  19.9 0.0215
Mean±SD
tinuous variables; stepwise multiple regression analy-
sis was also used.
Results
　 The clinical parameters at the baseline and the 
1-year follow up are summarized in Table 1.  
Anthropometric and body composition parameters such 
as body weight,  BMI and abdominal circumference 
were signiﬁcantly reduced with lifestyle modiﬁcation 
after 1 year.  Cr was signiﬁcantly decreased and 
eGFR was signiﬁcantly increased.  No subject was 
diagnosed as having metabolic syndrome and only one 
subject was diagnosed with reduced eGFR from base-
line to the 1-year follow up.  In addition,  2 subjects 
were identiﬁed as positive (＋) for proteinuria at 
baseline and 4 subjects were identiﬁed as trace posi-
tive at the 1-year follow up.
　 The relationship between eGFR and clinical 
parameters at baseline was evaluated.  There were no 
signiﬁcant relationships between eGFR and other 
clinical parameters at baseline (Table 2).
　 We further evaluated the relationship between 
changes in eGFR and changes in clinical parameters.  
Changes in eGFR were weakly correlated with 
changes in systolic blood pressure (r＝－0.306,  p＝
0.0260) (Table 3,  Fig.  1).  However,  changes in 
eGFR were not signiﬁcantly correlated with changes 
in other metabolic components.  We also used stepwise 
multiple regression analysis to evaluate the eﬀect of 
changes in clinical parameters,  i. e.  body weight,  
BMI,  abdominal circumference,  systolic blood pres-
sure,  diastolic blood pressure,  triglyceride,  HDL 
cholesterol and blood sugar,  on the change in eGFR,  
and found that only change in systolic blood pressure 
was signiﬁcant [Change in eGFR＝3.632－0.349 
(change in systolic blood pressure),  r2＝0.093,  p＝
0.0260].
　 Finally,  we further investigated the diﬀerence of 
change in eGFR between subjects who had diﬀerent 
levels of systolic blood pressure at baseline [Group L,  
systolic blood pressure＜140mmHg; Group H,  sys-
tolic blood pressure ≥ 140mmHg].  The changes in 
systolic blood pressure in Group H subjects (－1.20 
ml/min/1.73m2) was lower than that in Group L sub-
jects (4.9ml/min/1.73m2) after 1 year,  but not at a 
signiﬁcant level (p＝0.2822).
Discussion
　 The main objective of this study was to explore the 
link between changes in eGFR and changes in meta-
bolic syndrome components in Japanese women with a 
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Table 2　 Simple correlation analysis between eGFR and clinical 
parameters at baseline
r p
Body weight (kg) 0.082 0.5594
Body mass index (kg/m2) 0.033 0.8165
Abdominal circumference (cm) －0.154 0.2708
Systolic blood pressre (mmHg) －0.167 0.2333
Diastolic blood pressure (mmHg) －0.119 0.3958
Triglyceride (mg/dl) 0.123 0.3785
HDL cholesterol (mg/dl) －0.063 0.6566
Blood sugar (mg/dl) －0.193 0.1662
Table 3　 Simple correlation analysis between changes in eGFR 
and changes in clinical parameters with 1-year folIow up
r p
Body weight (kg) 0.188 0.1775
Body mass index (kg/m2) 0.181 0.1945
Abdominal circumference (cm) 0.253 0.0672
Systolic bIood pressre (mmHg) －0.306 0.0260
Diastolic blood pressure (mmHg) －0.112 0.4325
Triglyceride (mg/dl) 0.095 0.5006
HDL cholesterol (mg/dl) 0.227 0.1015
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Fig. 1　 Simple correlation analysis between changes in eGFR 
and changes in systolic blood pressure at 1-year follow up.
1-year follow up.  
　 Tanaka et al.  [6],  Ninomiya T et al.  [7] and Iseki 
et al.  [8] reported that metabolic syndrome,  using the 
modiﬁed ATP III deﬁnition [9],  was associated with 
CKD in the Japanese population.  Compared with 
subjects with 0 or 1 component of metabolic syn-
drome,  subjects with 2,  3 and 4 or more components 
had odds ratios of 1.13,  1.90 and 2.79 for CKD [7].  
In this study,  no subject was diagnosed as having 
metabolic syndrome,  using the Japanese criteria,  
either at baseline or at the 1-year follow up.  We have 
previously reported that the prevalence of metabolic 
syndrome was 3.6ｵ in Japanese women [10].  
However,  with lifestyle modiﬁcation after the initial 
health check-up,  eGFR was signiﬁcantly increased 
even in women without metabolic syndrome at the 
1-year follow-up.
　 Hypertension contributes to the development of 
renal injury and end-stage renal disease [11-15].  
Even high-normal blood pressure has been shown to be 
signiﬁcantly associated with development of CKD in 
both sexes.  Yamagata et al.  reported that the base-
line-adjusted predictor of developing CKD included 
age,  GFR,  hematuria,  hypertension,  diabetes,  serum 
lipids,  obesity,  smoking status and consumption of 
alcohol with 10-year follow up [11].  Tozawa et al.  
also reported a relative risk of 1.34 for end-stage 
renal failure for every increase of 10mmHg in systolic 
blood pressure in 51,878 women investigated [12].  In 
the present study,  there was no signiﬁcant relation-
ship between eGFR and systolic blood pressure at 
baseline.  However,  we revealed that,  with lifestyle 
modiﬁcation,  changes in systolic blood pressure were 
correlated with changes in eGFR in women without 
metabolic syndrome.  Therefore,  the clinical impact of 
hypertension was noted.
　 Potential limitations remain in our study.  First,  
the small sample size in our study makes it diﬃcult to 
infer causality between eGFR and hypertension.  
Second,  we also could not reveal the mechanism of the 
linkage between eGFR and hypertension.  Further 
prospective studies are needed in Japanese subjects.  
Third,  most of the enrolled subjects were not diag-
nosed as CKD at baseline.  Therefore,  the results in 
this study may not apply for patients with CKD.
　 In conclusion,  a decrease in systolic blood pressure 
with lifestyle modiﬁcation was associated with an 
increase in eGFR.  Therefore,  lifestyle modiﬁcation 
may be a necessary and useful measure for the preven-
tion of CKD.
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